A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
Status:
Not yet recruiting
Trial end date:
2025-06-10
Target enrollment:
Participant gender:
Summary
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular
resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and
pulmonary hypertension (PH) Group 2.